Literature DB >> 25189642

Morphologic and immunohistochemical features of malignant peripheral nerve sheath tumors and cellular schwannomas.

Melike Pekmezci1, David E Reuss2, Angela C Hirbe3, Sonika Dahiya4, David H Gutmann5, Andreas von Deimling2, Andrew E Horvai6, Arie Perry7.   

Abstract

Cellular schwannoma is an uncommon, but well-recognized, benign peripheral nerve sheath tumor, which can be misdiagnosed as malignant peripheral nerve sheath tumor. To develop consensus diagnostic criteria for cellular schwannoma, we reviewed 115 malignant peripheral nerve sheath tumor and 26 cellular schwannoma cases from two institutions. Clinical data were retrieved from the electronic medical records, and morphologic features, maximal mitotic counts, Ki67 labeling indices, and immunohistochemical profiles (SOX10, SOX2, p75NTR, p16, p53, EGFR, and neurofibromin) were assessed. Several features distinguish cellular schwannoma from malignant peripheral nerve sheath tumor. First, in contrast to patients with malignant peripheral nerve sheath tumor, no metastases or disease-specific deaths were found in patients with cellular schwannoma. More specifically, 5-year progression-free survival rates were 100 and 18%, and 5-year disease-specific survival rates were 100 and 32% for cellular schwannoma and malignant peripheral nerve sheath tumor, respectively. Second, the presence of Schwannian whorls, a peritumoral capsule, subcapsular lymphocytes, macrophage-rich infiltrates, and the absence of fascicles favored the diagnosis of cellular schwannoma, while the presence of perivascular hypercellularity, tumor herniation into vascular lumens, and necrosis favor malignant peripheral nerve sheath tumor. Third, complete loss of SOX10, neurofibromin or p16 expression, or the presence of EGFR immunoreactivity was specific for malignant peripheral nerve sheath tumor (P<0.001 for each). Expression of p75NTR was observed in 80% of malignant peripheral nerve sheath tumors compared with 31% of cellular schwannomas (P<0.001). Fourth, Ki-67 labeling indices ≥20% were highly predictive of malignant peripheral nerve sheath tumor (87% sensitivity and 96% specificity). Taken together, the combinations of these histopathological and immunohistochemical features provide useful criteria to distinguish between malignant peripheral nerve sheath tumor and cellular schwannoma with high sensitivity and specificity. Additional retrospective and prospective multicenter studies with larger data sets will be required to validate these findings.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25189642      PMCID: PMC6816504          DOI: 10.1038/modpathol.2014.109

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  32 in total

1.  Malignant transformation of neurofibromas in neurofibromatosis 1 is associated with CDKN2A/p16 inactivation.

Authors:  G P Nielsen; A O Stemmer-Rachamimov; Y Ino; M B Moller; A E Rosenberg; D N Louis
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

2.  Clinical and molecular prognostic predictors of malignant peripheral nerve sheath tumor.

Authors:  Q Fan; J Yang; G Wang
Journal:  Clin Transl Oncol       Date:  2013-06-08       Impact factor: 3.405

3.  Sox10 and S100 in the diagnosis of soft-tissue neoplasms.

Authors:  Jason R Karamchandani; Torsten O Nielsen; Matt van de Rijn; Robert B West
Journal:  Appl Immunohistochem Mol Morphol       Date:  2012-10

4.  Neurofibromin specific antibody differentiates malignant peripheral nerve sheath tumors (MPNST) from other spindle cell neoplasms.

Authors:  David E Reuss; Antje Habel; Christian Hagenlocher; Jana Mucha; Ulrike Ackermann; Claudia Tessmer; Jochen Meyer; David Capper; Gerhard Moldenhauer; Victor Mautner; Pierre-Olivier Frappart; Jens Schittenhelm; Christian Hartmann; Christian Hagel; Kathrin Katenkamp; Iver Petersen; Gunhild Mechtersheimer; Andreas von Deimling
Journal:  Acta Neuropathol       Date:  2014-01-25       Impact factor: 17.088

5.  Epidermal growth factor receptor expression and mutational analysis in synovial sarcomas and malignant peripheral nerve sheath tumors.

Authors:  Hussein Tawbi; Dafydd Thomas; David R Lucas; J Sybil Biermann; Scott M Schuetze; Anita L Hart; Rashmi Chugh; Laurence H Baker
Journal:  Oncologist       Date:  2008-04

6.  Spinal malignant nerve-sheath tumor or cellular schwannoma? A striking difference in prognosis.

Authors:  M T Seppälä; M J Haltia
Journal:  J Neurosurg       Date:  1993-10       Impact factor: 5.115

7.  Diagnostic utility of SOX10 to distinguish malignant peripheral nerve sheath tumor from synovial sarcoma, including intraneural synovial sarcoma.

Authors:  Yuna Kang; Melike Pekmezci; Andrew L Folpe; Ayca Ersen; Andrew E Horvai
Journal:  Mod Pathol       Date:  2013-08-09       Impact factor: 7.842

8.  Expression of c-Jun and Sox-2 in human schwannomas and traumatic neuromas.

Authors:  Aditya Shivane; David B Parkinson; Sylwia Ammoun; Clemens O Hanemann
Journal:  Histopathology       Date:  2013-01-30       Impact factor: 5.087

Review 9.  Survival meta-analyses for >1800 malignant peripheral nerve sheath tumor patients with and without neurofibromatosis type 1.

Authors:  Matthias Kolberg; Maren Høland; Trude H Agesen; Helge R Brekke; Knut Liestøl; Kirsten S Hall; Fredrik Mertens; Piero Picci; Sigbjørn Smeland; Ragnhild A Lothe
Journal:  Neuro Oncol       Date:  2012-11-15       Impact factor: 12.300

10.  Genomic amplification and high expression of EGFR are key targetable oncogenic events in malignant peripheral nerve sheath tumor.

Authors:  Xiaoling Du; Jilong Yang; Antti Ylipää; Ze Zhu
Journal:  J Hematol Oncol       Date:  2013-12-17       Impact factor: 17.388

View more
  36 in total

1.  Significance of H3K27me3 loss in the diagnosis of malignant peripheral nerve sheath tumors.

Authors:  Melike Pekmezci; Areli K Cuevas-Ocampo; Arie Perry; Andrew E Horvai
Journal:  Mod Pathol       Date:  2017-08-04       Impact factor: 7.842

2.  Comparision of New Diagnostic Tools for Malignant Peripheral Nerve Sheath Tumors.

Authors:  Ayca Ersen; Melike Pekmezci; Andrew L Folpe; Tarik Tihan
Journal:  Pathol Oncol Res       Date:  2016-10-12       Impact factor: 3.201

Review 3.  What's new in nerve sheath tumors.

Authors:  Anders Meyer; Steven D Billings
Journal:  Virchows Arch       Date:  2019-11-09       Impact factor: 4.064

4.  PDGFB Rearrangements in Dermatofibrosarcoma Protuberans of the Vulva: A Study of 11 Cases Including Myxoid and Fibrosarcomatous Variants.

Authors:  Khadijeh Jahanseir; Deyin Xing; Patricia T Greipp; William R Sukov; Gary L Keeney; Brooke E Howitt; J Kenneth Schoolmeester
Journal:  Int J Gynecol Pathol       Date:  2018-11       Impact factor: 2.762

5.  Assessment of paraspinal neurogenic tumors with diffusion-weighted MR imaging.

Authors:  Ahmed Abdel Khalek Abdel Razek; Germeen Albair Ashmalla
Journal:  Eur Spine J       Date:  2017-08-18       Impact factor: 3.134

Review 6.  Histopathologic evaluation of atypical neurofibromatous tumors and their transformation into malignant peripheral nerve sheath tumor in patients with neurofibromatosis 1-a consensus overview.

Authors:  Markku M Miettinen; Cristina R Antonescu; Christopher D M Fletcher; Aerang Kim; Alexander J Lazar; Martha M Quezado; Karlyne M Reilly; Anat Stemmer-Rachamimov; Douglas R Stewart; David Viskochil; Brigitte Widemann; Arie Perry
Journal:  Hum Pathol       Date:  2017-05-24       Impact factor: 3.466

7.  Malignant peripheral nerve sheath tumor (MPNST) in the spine: a retrospective analysis of clinical and molecular prognostic factors.

Authors:  Ting Wang; Huabin Yin; Shuai Han; Xinhai Yang; Jing Wang; Quan Huang; Wangjun Yan; Wang Zhou; Jianru Xiao
Journal:  J Neurooncol       Date:  2015-01-20       Impact factor: 4.130

8.  TFG-MET fusion in an infantile spindle cell sarcoma with neural features.

Authors:  Uta Flucke; Max M van Noesel; Marc Wijnen; Lei Zhang; Chun-Liang Chen; Yun-Shao Sung; Cristina R Antonescu
Journal:  Genes Chromosomes Cancer       Date:  2017-06-27       Impact factor: 5.006

9.  Loss of H3K27 tri-methylation is a diagnostic marker for malignant peripheral nerve sheath tumors and an indicator for an inferior survival.

Authors:  Arjen H G Cleven; Ghadah A Al Sannaa; Inge Briaire-de Bruijn; Davis R Ingram; Matt van de Rijn; Brian P Rubin; Maurits W de Vries; Kelsey L Watson; Keila E Torres; Wei-Lien Wang; Sjoerd G van Duinen; Pancras C W Hogendoorn; Alexander J Lazar; Judith V M G Bovée
Journal:  Mod Pathol       Date:  2016-03-18       Impact factor: 7.842

10.  EANO guideline on the diagnosis and treatment of vestibular schwannoma.

Authors:  Roland Goldbrunner; Michael Weller; Jean Regis; Morten Lund-Johansen; Pantelis Stavrinou; David Reuss; D Gareth Evans; Florence Lefranc; Kita Sallabanda; Andrea Falini; Patrick Axon; Olivier Sterkers; Laura Fariselli; Wolfgang Wick; Joerg-Christian Tonn
Journal:  Neuro Oncol       Date:  2020-01-11       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.